Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY

Why It Matters

The breakout performance of IM8 validates premium, subscription‑based consumer health models and positions Prenetics for scalable global growth, while the balance‑sheet strengthening gives it runway to invest in market expansion and profitability.

Key Takeaways

• IM8 hit $120M ARR within 12 months.
• FY2025 revenue jumped 480% to $92.4M.
• Quarterly subscriptions raised AOV to $233.
• Liquidity rose to $171M after $72M+ divestitures.
• IM8 gross margin held near 60%.

Pulse Analysis

IM8’s meteoric rise reflects a broader shift toward premium, science‑backed supplements that blend performance and longevity. Leveraging David Beckham’s co‑founder status and high‑profile athlete ambassadors, the brand achieved rapid product‑market fit across more than 30 countries, with the United States accounting for just under 40% of revenue. This diversified geographic footprint reduces reliance on any single market and underscores the growing consumer appetite for personalized health solutions that promise measurable outcomes.

Prenetics’ strategic divestitures of non‑core assets—ACT Genomics, Europa, and Insighta—cleared operational complexity and injected roughly $135 million in cash, lifting total adjusted liquidity to $171 million and eliminating debt. The resulting leaner structure improves gross‑margin leverage, as evidenced by IM8’s stable 60% margin despite higher logistics costs. With operating expenses scaling slower than revenue, adjusted EBITDA loss narrowed dramatically, setting a clear pathway to profitability as the company scales.

The pivot to quarterly subscription plans is a decisive lever for cash‑flow acceleration and customer lifetime value. By increasing the blended average order value from $110 to $233 within months, Prenatics shortens the payback period and enhances capital efficiency, achieving a projected 3× LTV:CAC ratio. Coupled with strong retention metrics and expanding global distribution, these dynamics position IM8 to exceed its $200 million revenue target for 2026 and to become a category‑defining health brand worldwide.